FDA Approves Targeted Drug Combination, Belzutifan Plus Lenvatinib, After Immunotherapy For Patients With Most Common Type of Kidney Cancer

The approval, which was announced on Sept. 24, 2026, is for patients with clear cell renal cell carcinoma, a subtype that makes up about 80% of all kidney cancers diagnosed in adults, after immunotherapy with a PD-1 or PD-L1 inhibitor stops working.

These treatments help immune cells recognize and attack cancer by releasing one of the “brakes” tumors use to evade the immune system.

Who May Be Eligible?

Renal cell carcinoma is the most common form of kidney cancer. Clear cell renal cell carcinoma, named for the pale appearance of the cancer cells under a microscope, is its most common subtype.

The approval is specifically for patients with advanced disease, which generally means that the cancer cannot be removed completely with surgery, has grown into nearby structures, or has spread to another part of the body.

The new FDA indication applies to adults whose treatment history includes a PD-1 or PD-L1 inhibitor. Some patients in the trial that led to the approval, LITESPARK-011, also received a drug targeting vascular endothelial growth factor receptors, but prior treatment with one of these drugs is not required by the new combination’s FDA indication.

Oncologists will need to decide whether the newly approved combination is right for patients on a case by case basis, considering factors like the patient’s previous treatments, heart and lung health, blood counts, kidney and liver function, blood pressure, and other medical conditions.

Two Drugs Attacking Different Cancer Pathways

Both belzutifan and lenvatinib work by targeting proteins associated with cancer growth.

Belzutifan blocks a protein called hypoxia-inducible factor 2 alpha, or HIF-2 alpha. Clear cell kidney cancers can use this pathway to adapt to low-oxygen conditions and activate genes that support tumor growth and abnormal blood vessel formation.

Lenvatinib is a tyrosine kinase inhibitor that blocks several growth signals, including vascular endothelial growth factor receptors. By interfering with these signals, it can limit the cancer’s ability to build the blood supply it needs.

Researchers combined the drugs to target related parts of kidney cancer biology from different directions.

What Did the Trial Find?

The approval was based on LITESPARK-011, a phase 3 study involving 747 people with previously treated advanced clear cell kidney cancer. Participants were randomly assigned to receive belzutifan plus lenvatinib or cabozantinib, another established oral targeted therapy used after immunotherapy.

Results were promising:

• Patients receiving the combination went a median of 14.6 months before the cancer worsened or they died, compared with 10.6 months among those receiving cabozantinib.
• The hazard ratio was 0.74, meaning the combination was associated with a 26% lower risk of progression or death at any point during the study. That does not mean patients lived 26% longer.
• Tumors shrank by a predefined amount in 53% of patients receiving belzutifan and lenvatinib, compared with 40% receiving cabozantinib.

At the final overall-survival analysis, median survival was 33.7 months with the combination and 28.6 months with cabozantinib. The difference was not statistically significant.

The trial therefore showed better control of the cancer, but it did not prove that the combination extends life compared with cabozantinib.

“The most impressive result was that for patients who responded, their likelihood of continuing to respond was much higher on the combination at almost two years compared to 12 months on cabozantinib,” Dr. Srinivas says.

“However, when you combine two drugs, there is an increased price that you pay in toxicity. The highest toxicity was anemia and fatigue for patients who were on the combination; this combination did not result in increased longevity despite having these positive results,” Dr. Srinivas added.

Side Effects Require Close Monitoring

This is an intensive two-drug regimen. Serious adverse reactions occurred in 54% of patients who received the combination.

Belzutifan can cause severe anemia and dangerously low oxygen levels.

In the trial:

• Decreased hemoglobin occurred in 87% of patients receiving the combination, and 20% developed grade 3 anemia or required a blood transfusion.
• Hypoxia (low levels of oxygen in tissues) occurred in 16%, including more serious grade 3 or 4 events in 12%.

Lenvatinib can cause high blood pressure, kidney or liver problems, protein in the urine, diarrhea, bleeding, thyroid dysfunction, and impaired wound healing. The combination can also cause heart failure or reduced heart-pumping function.

To monitor progress and keep an eye on potential side effects, patients may need regular:

• Blood tests
• Oxygen measurements
• Blood pressure checks
• Heart imaging (occasional)

Treatment can be paused, reduced, or stopped when side effects become unsafe.

Patients and their doctors must weigh the likelihood of controlling the cancer against the risks of two targeted drugs and the other treatments available after immunotherapy.

Questions To Ask Your Doctor

• Does my tumor have a clear cell component, and do I meet the FDA-approved criteria for this combination?
• How does belzutifan plus lenvatinib compare with the other treatments available after my immunotherapy?
• Do my blood counts, oxygen level, blood pressure, and heart function make this regimen safe for me?
• What symptoms of anemia, low oxygen, high blood pressure, or heart problems should I report immediately?
• How often will I need blood tests, oxygen checks, urine testing, or heart imaging?
• If I develop side effects, can the doses be reduced or temporarily stopped?

Learn more about SurvivorNet's rigorous medical review process.

---